Sartorius Stedim Biotech SA banner

Sartorius Stedim Biotech SA
PAR:DIM

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
PAR:DIM
Watchlist
Price: 177.9 EUR -1.93% Market Closed
Market Cap: €17.3B

Gross Margin

45.6%
Current
No historical data
Comparison unavailable

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
45.6%
=
Gross Profit
€1.3B
/
Revenue
€2.9B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
45.6%
=
Gross Profit
€1.3B
/
Revenue
€2.9B

Peer Comparison

Country Company Market Cap Gross
Margin
FR
Sartorius Stedim Biotech SA
PAR:DIM
17.3B EUR
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.1T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
204.9B USD
Loading...
US
Danaher Corp
NYSE:DHR
153.2B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
46.3T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
35.4B CHF
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
280B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
36.9B USD
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
31.9B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.3B USD
Loading...
US
Waters Corp
NYSE:WAT
22.8B USD
Loading...

Market Distribution

In line with most companies in France
Percentile
40th
Based on 2 087 companies
40th percentile
45.6%
Low
-1 220.2% — 34%
Typical Range
34% — 70.2%
High
70.2% — 509.6%
Distribution Statistics
France
Min -1 220.2%
30th Percentile 34%
Median 53.6%
70th Percentile 70.2%
Max 509.6%

Sartorius Stedim Biotech SA
Glance View

Sartorius Stedim Biotech SA has been weaving the intricate threads of biotechnology innovation into a fabric of global influence and success. Established as a pivotal player in the biopharmaceutical industry, Sartorius Stedim Biotech has carved out a niche by offering sophisticated products and solutions that cater to the unique needs of biopharmaceutical manufacturers. The company’s portfolio is a testament to the fusion of scientific ingenuity and relentless pursuit of quality. Spanning filtration and purification solutions, fermentation equipment, and fluid management systems, their offerings ensure that complex biological drugs, including vaccines and monoclonal antibodies, are produced efficiently and safely. Sartorius Stedim Biotech’s endeavor is not just about supplying equipment; it’s about providing integrated solutions that optimize the entire production process, ensuring consistency, scalability, and compliance in industries bound by strict regulatory oversight. The company generated revenue through its comprehensive range of products and services that address every step of the biomanufacturing process. Their business model hinges on fostering long-term relationships with clients by offering tailored solutions that enhance productivity and reduce time-to-market for new therapies. Beyond direct sales of high-value equipment, Sartorius Stedim Biotech also capitalizes on recurring revenue streams generated from consumables and maintenance services essential for the ongoing operation of their systems. By continuously innovating and expanding its product lines, the company stays at the forefront of technological advancements, enabling clients to tackle the ever-evolving challenges of bioproduction. As the global biopharmaceutical industry surges forward, driven by increasing demand for biologics, Sartorius Stedim Biotech remains poised to maintain its role as an indispensable ally to firms dedicated to transforming the health landscape through revolutionary therapies.

DIM Intrinsic Value
164.5 EUR
Overvaluation 8%
Intrinsic Value
Price
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
45.6%
=
Gross Profit
€1.3B
/
Revenue
€2.9B
What is Sartorius Stedim Biotech SA's current Gross Margin?

The current Gross Margin for Sartorius Stedim Biotech SA is 45.6%, which is in line with its 3-year median of 45.6%.

How has Gross Margin changed over time?

Over the last 3 years, Sartorius Stedim Biotech SA’s Gross Margin has decreased from 52.3% to 45.6%. During this period, it reached a low of 41.8% on Sep 30, 2024 and a high of 52.5% on Dec 31, 2022.

Back to Top